Problem being addressed:
To manage high-risk infected patients, a typical series of events involves putting patients on High Flow Nasal Oxygen or CPAP before going over to the ventilator stage. Since India faces a strong shortage of ventilators if the infection spreads to a wider scale, it is imperative that most patients are cured at the stage previous to that, which will require the use of HFNC or CPAP devices. Furthermore, despite the massive purchase of invasive ventilators, shortage of respiratory therapists and clinicians may make invasive ventilation difficult or risky in many centers (barotrauma etc.) prescribe) + innovative ways to administer the test so that we can test at scale.
InnAccel is developing a non-invasive ventilation system that provides respiratory support to moderately severe hypoxemic Covid patients, before incubating them and starting invasive ventilation. It is doing so by providing CPAP with a helmet-patient interface that prevents the spread of infections and developing HFNC devices which provide high-flow oxygen. The system is equipped to deal with infrastructural challenges such as unreliable electricity, compressed oxygen and is designed for use by semi-skilled health workers with minimal training
Siraj Dhanani (CEO; entrepreneur, angel investor, healthcare professional) and A. Vijayarajan: (CTO; Ex. VP GE Healthcare India, HP India) lead an experienced, interdisciplinary team of 30 passionate individuals